Oxidative stress and nucleic acid oxidation in patients with chronic kidney disease

Chih-Chien Sung, Yu-Chuan Hsu, Chun-Chi Chen, Yuh-Feng Lin, Chia-Chao Wu, Chih-Chien Sung, Yu-Chuan Hsu, Chun-Chi Chen, Yuh-Feng Lin, Chia-Chao Wu

Abstract

Patients with chronic kidney disease (CKD) have high cardiovascular mortality and morbidity and a high risk for developing malignancy. Excessive oxidative stress is thought to play a major role in elevating these risks by increasing oxidative nucleic acid damage. Oxidative stress results from an imbalance between reactive oxygen/nitrogen species (RONS) production and antioxidant defense mechanisms and can cause vascular and tissue injuries as well as nucleic acid damage in CKD patients. The increased production of RONS, impaired nonenzymatic or enzymatic antioxidant defense mechanisms, and other risk factors including gene polymorphisms, uremic toxins (indoxyl sulfate), deficiency of arylesterase/paraoxonase, hyperhomocysteinemia, dialysis-associated membrane bioincompatibility, and endotoxin in patients with CKD can inhibit normal cell function by damaging cell lipids, arachidonic acid derivatives, carbohydrates, proteins, amino acids, and nucleic acids. Several clinical biomarkers and techniques have been used to detect the antioxidant status and oxidative stress/oxidative nucleic acid damage associated with long-term complications such as inflammation, atherosclerosis, amyloidosis, and malignancy in CKD patients. Antioxidant therapies have been studied to reduce the oxidative stress and nucleic acid oxidation in patients with CKD, including alpha-tocopherol, N-acetylcysteine, ascorbic acid, glutathione, folic acid, bardoxolone methyl, angiotensin-converting enzyme inhibitor, and providing better dialysis strategies. This paper provides an overview of radical production, antioxidant defence, pathogenesis and biomarkers of oxidative stress in patients with CKD, and possible antioxidant therapies.

Figures

Figure 1
Figure 1
Synthesis of reactive oxygen species (ROS) in patients with chronic kidney disease (CKD). Excessive reactive ROS including ONOO−, OH−, and OCl− are generated from oxygen through several main enzymes (NADPH oxidase, superoxide dismutase (SOD), and myeloperoxidase (MPO)). Several factors can also increase ROS generation, including cytokines (IL-8, IL-1β, and TNF-α) released from activated monocytes, uremic toxin (indoxyl sulfate), and endotoxin (LPS) from the HC procedure. The resulting excessive ROS can lead to nitrosative (ONOO−), chlorinative (OCl−), and oxidative (OH−) modifications to lipids, proteins, and DNA.
Figure 2
Figure 2
Impairment of antioxidant system in patients with CKD. Antioxidant systems, including nonenzymatic systems (thiol, alpha-tocopherol, and ascorbic acid) and enzymatic systems (superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx)), are impaired or deficient in patients with CKD. Hyperhomocysteinemia can lead to inhibition of the activity of the antioxidant enzymes SOD and GPx. GR: glutathione reductase; GSH: glutathione; GSSG: glutathione disulfide; Se: selenium.

References

    1. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. The Lancet. 1999;354(9173):93–99.
    1. Teschner M, Garte C, Rückle-Lanz H, et al. Incidence and spectrum of malignant disease among dialysis patients in North Bavaria. Deutsche Medizinische Wochenschrift. 2002;127(47):2497–2502.
    1. Vaziri ND, Oveisi F, Ding Y. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney International. 1998;53(6):1748–1754.
    1. Tepel M, Echelmeyer M, Orie NN, Zidek W. Increased intracellular reactive oxygen species in patients with end-stage renal failure: effect of hemodialysis. Kidney International. 2000;58(2):867–872.
    1. Galle J. Oxidative stress in chronic renal failure. Nephrology Dialysis Transplantation. 2001;16(11):2135–2137.
    1. Palleschi S, de Angelis S, Diana L, et al. Reliability of oxidative stress biomarkers in hemodialysis patients: a comparative study. Clinical Chemistry and Laboratory Medicine. 2007;45(9):1211–1218.
    1. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 3rd edition. Oxford, UK: Oxford University Press; 1999.
    1. Errakonda PR, Paladugu R, Bitla AR, et al. Effect of a single hemodialysis session on endothelial dysfunction. Journal of Nephrology. 2011;24(1):83–90.
    1. Dursun B, Dursun E, Suleymanlar G, et al. Carotid artery intima-media thickness correlates with oxidative stress in chronic haemodialysis patients with accelerated atherosclerosis. Nephrology Dialysis Transplantation. 2008;23(5):1697–1703.
    1. Diplock AT, Charleux J-L, Crozier-Willi G, et al. Functional food science and defence against reactive oxidative. British Journal of Nutrition. 1998;80(supplement 1):S77–S112.
    1. Ames BN. Endogenous oxidative DNA damage, aging and cancer. Free Radical Research Communications. 1989;7(3–6):121–128.
    1. Schulz WA, Obendorf MSW, Sies H. Localization of strand breaks in plasmid DNA treated with reactive oxygen species. Methods in Enzymology. 1994;234:45–51.
    1. Beckman KB, Ames BN. Oxidative decay of DNA. Journal of Biological Chemistry. 1997;272(32):19633–19636.
    1. Descamps-Latscha B, Drüeke T, Witko-Sarsat V. Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Seminars in Dialysis. 2001;14(3):193–199.
    1. Bedard K, Krause K-H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiological Reviews. 2007;87(1):245–313.
    1. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proceedings of the National Academy of Sciences of the United States of America. 1990;87(4):1620–1624.
    1. Davies KJ. Protein damage and degradation by oxygen radicals. I. general aspects. Journal of Biological Chemistry. 1987;262(20):9895–9901.
    1. Wolff SP, Garner A, Dean RT. Free radicals, lipids and protein degradation. Trends in Biochemical Sciences. 1986;11(1):27–31.
    1. Imlay JA, Linn S. DNA damage and oxygen radical toxicity. Science. 1988;240(4857):1302–1309.
    1. Locatelli F, Canaud B, Eckardt K-U, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging treat to patient outcome. Nephrology Dialysis Transplantation. 2003;18(7):1272–1280.
    1. Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nature Medicine. 2007;13(10):1176–1184.
    1. Kalantar-Zadeh K, Brennan M-L, Hazen SL. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. The American Journal of Kidney Diseases. 2006;48(1):59–68.
    1. Cristol JP, Canaud B, Rabesandratana H, Gaillard I, Serre A, Mion C. Enhancement of reactive oxygen species production and cell surface markers expression due to haemodialysis. Nephrology Dialysis Transplantation. 1994;9(4):389–394.
    1. Chen M-F, Chang C-L, Liou S-Y. Increase in resting levels of superoxide anion in the whole blood of uremic patients on chronic hemodialysis. Blood Purification. 1998;16(5):290–300.
    1. Ghezzi P, Bonetto V, Fratelli M. Thiol-disulfide balance: from the concept of oxidative stress to that of redox regulation. Antioxidants and Redox Signaling. 2005;7(7-8):964–972.
    1. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Seminars in Dialysis. 2009;22(6):636–643.
    1. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. Perspectives in renal medicine: the elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney International. 2002;62(5):1524–1538.
    1. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation. 2004;109(3):369–374.
    1. Gongora MC, Lob HE, Landmesser U, et al. Loss of extracellular superoxide dismutase leads to acute lung damage in the presence of ambient air: a potential mechanism underlying adult respiratory distress syndrome. The American Journal of Pathology. 2008;173(4):915–926.
    1. Kobayashi M, Sugiyama H, Wang D-H, et al. Catalase deficiency renders remnant kidneys more susceptible to oxidant tissue injury and renal fibrosis in mice. Kidney International. 2005;68(3):1018–1031.
    1. Ursini F, Maiorino M, Gregolin C. The selenoenzyme phospholipid hydroperoxide glutathione peroxidase. Biochimica et Biophysica Acta. 1985;839(1):62–70.
    1. Avissar N, Ornt DB, Yagil Y, et al. Human kidney proximal tubules are the main source of plasma glutathione peroxidase. The American Journal of Physiology. 1994;266(2):C367–C375.
    1. Wood ZA, Schröder E, Harris JR, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends in Biochemical Sciences. 2003;28(1):32–40.
    1. Canaud B, Cristol J-P, Morena M, Leray-Moragues H, Bosc J-Y, Vaussenat F. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purification. 1999;17(2-3):99–106.
    1. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radical Biology and Medicine. 1996;21(6):845–853.
    1. Bonomini M, Albertazzi A. Selenium in uremia. Artificial Organs. 1995;19(5):443–448.
    1. Tarng D-C, Tsai T-J, Chen W-T, Liu T-Y, Wei Y-H. Effect of human OGG1 1245C→G gene polymorphism on 8-hydroxy-2′-deoxyguanosine levels of leukocyte DNA among patients undergoing chronic hemodialysis. Journal of the American Society of Nephrology. 2001;12(11):2338–2347.
    1. Kohno T, Shinmura K, Tosaka M, et al. Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene. 1998;16(25):3219–3225.
    1. Trabulus S, Guven GS, Altiparmak MR, et al. DNA repair XRCC1 Arg399Gln polymorphism is associated with the risk of development of end-stage renal disease. Molecular Biology Reports. 2012;39:6995–7001.
    1. Cai Z, Chen H, Tao J, et al. Association of base excision repair gene polymorphisms with ESRD risk in a Chinese population. Oxidative Medicine and Cellular Longevity. 2012;2012928421
    1. Crawford A, Fassett RG, Coombes JS, et al. Glutathione peroxidase, superoxide dismutase and catalase genotypes and activities and the progression of chronic kidney disease. Nephrology Dialysis Transplantation. 2011;26(9):2806–2813.
    1. Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg? Seminars in Dialysis. 2004;17(6):449–454.
    1. Crawford A, Fassett RG, Geraghty DP, et al. Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene. 2012;501:89–103.
    1. Lin Y-S, Hung S-C, Wei Y-H, Tarng D-C. GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients. Journal of the American Society of Nephrology. 2009;20(2):405–415.
    1. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. The Lancet. 2000;356(9237):1213–1218.
    1. Mann JFE, Lonn EM, Yi Q, et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE Study. Kidney International. 2004;65(4):1375–1380.
    1. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003;107(7):992–995.
    1. Tarng D-C, Liu T-Y, Huang T-P. Protective effect of vitamin C on 8-hydroxy-2′-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients. Kidney International. 2004;66(2):820–831.
    1. Kayabasi H, Yilmaz Z, Sit D, Kadiroglu AK, Yilmaz E. The effects of Losartan on oxidative stress and inflammation in non-diabetic patients undergoing chronic hemodialysis. European Review For Medical and Pharmacological Sciences. 2013;17:235–242.
    1. Delfino VDA, de Andrade Vianna AC, Mocelin AJ, Barbosa DS, Mise RA, Matsuo T. Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients. Nutrition. 2007;23(3):242–247.
    1. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. The New England Journal of Medicine. 2011;365(4):327–336.
    1. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney International. 2004;65(3):1009–1016.
    1. Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. The American Journal of Nephrology. 2007;27(1):30–35.
    1. Tumur Z, Shimizu H, Enomoto A, Miyazaki H, Niwa T. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-κB activation. The American Journal of Nephrology. 2010;31(5):435–441.
    1. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH. The kidney and homocysteine metabolism. Journal of the American Society of Nephrology. 2001;12(10):2181–2189.
    1. Massy ZA, Ceballos I, Chadefaux-Vekemens B, et al. Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients. Kidney International. 2001;59(supplement)(78):S243–S245.
    1. Ingrosso D, Cimmino A, Perna AF, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. The Lancet. 2003;361(9370):1693–1699.
    1. Dodget JE, Okano M, Dick F, et al. Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization. Journal of Biological Chemistry. 2005;280(18):17986–17991.
    1. Gugliucci A, Kotani K, Kimura S. Paraoxonase 1 in chronic kidney failure. Journal of Lipids. 2012;2012:10 pages.726048
    1. Tucker PS, Dalbo VJ, Han T, Kingsley MI. Clinical and research markers of oxidative stress in chronic kidney disease. Biomarkers. 2013;18:103–115.
    1. Ward RA, McLeish KR. Oxidant stress in hemodialysis patients: what are the determining factors? Artificial Organs. 2003;27(3):230–236.
    1. Wu C-C, Chen J-S, Wu W-M, et al. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrology Dialysis Transplantation. 2005;20:1134–1139.
    1. Nguyen AT, Lethias C, Zingraff J. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney International. 1985;28(2):158–167.
    1. Ward RA, Ouseph R, McLeish KR. Effects of high-flux hemodialysis on oxidant stress. Kidney International. 2003;63(1):353–359.
    1. Maggi E, Bellazzi R, Falaschi F, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney International. 1994;45(3):876–883.
    1. Ramos LF, Shintani A, Ikizler TA, Himmelfarb J. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. Journal of the American Society of Nephrology. 2008;19(3):593–599.
    1. Chen J-L, Huang Y-J, Pan C-H, Hu C-W, Chao M-R. Determination of urinary malondialdehyde by isotope dilution LC-MS/MS with automated solid-phase extraction: a cautionary note on derivatization optimization. Free Radical Biology and Medicine. 2011;51(9):1823–1829.
    1. Paul JL, Sall N-D, Soni T, et al. Lipid peroxidation abnormalities in hemodialyzed patients. Nephron. 1993;64(1):106–109.
    1. Esterbauer H, Schaur RJ, Zollner H. Chemistry and Biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biology and Medicine. 1991;11(1):81–128.
    1. Miyata T, Kurokawa K, van Ypersele de Strihou C. Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney International. 2000;58(76) supplement:S120–S125.
    1. Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney International. 2006;70(12):2109–2115.
    1. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ., II Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(22):10721–10725.
    1. Morena M, Delbosc S, Dupuy A-M, Canaud B, Cristol J-P. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodialysis International. 2005;9(1):37–46.
    1. Ramos R, Martínez-Castelao A. Lipoperoxidation and hemodialysis. Metabolism. 2008;57(10):1369–1374.
    1. Caimi G, Carollo C, Montana M, Iatrino R, Bondì B, Lo Presti R. Nitric oxide metabolites, leukocyte activation markers and oxidative status in dialyzed subjects. Blood Purification. 2009;27(2):194–198.
    1. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International. 1996;49(5):1304–1313.
    1. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Seminars in Nephrology. 2004;24(4):354–365.
    1. Erdoğan C, Unlüçerçi Y, Türkmen A, Kuru A, Cetin O, Bekpinar S. The evaluation of oxidative stress in patients with chronic renal failure. Clinica Chimica Acta. 2002;322:157–161.
    1. Pischetsrieder M, Seidel W, Münch G, Schinzel R. N2-(1-carboxyethyl)deoxyguanosine, a nonenzymatic glycation adduct of DNA, induces single-strand breaks and increases mutation frequencies. Biochemical and Biophysical Research Communications. 1999;264(2):544–549.
    1. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Molecular and Cellular Biochemistry. 2004;266(1-2):37–56.
    1. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutation Research. 1997;387(3):147–163.
    1. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chemico-Biological Interactions. 2006;160(1):1–40.
    1. Collins A. Comparison of different methods of measuring 8-oxoguanine as a marker of oxidative DNA damage. Free Radical Research. 2000;32(4):333–341.
    1. Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2′-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. Journal of Environmental Science and Health. 2009;27(2):120–139.
    1. Orhan H, van Holland B, Krab B, et al. Evaluation of a multi-parameter biomarker set for oxidative damage in man: increased urinary excretion of lipid, protein and DNA oxidation products after one hour of exercise. Free Radical Research. 2004;38(12):1269–1279.
    1. Gedik CM, Boyle SP, Wood SG, Vaughan NJ, Collins AR. Oxidative stress in humans: validation of biomarkers of DNA damage. Carcinogenesis. 2002;23(9):1441–1446.
    1. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutation Research. 1997;387(3):147–163.
    1. Tarng D-C, Huang T-P, Wei Y-H, et al. 8-Hydroxy-2′-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. The American Journal of Kidney Diseases. 2000;36(5):934–944.
    1. Tarng D-C, Chen TW, Huang T-P, Chen C-L, Liu T-Y, Wei Y-H. Increased oxidative damage to peripheral blood leukocyte DNA in chronic peritoneal dialysis patients. Journal of the American Society of Nephrology. 2002;13(5):1321–1330.
    1. Hu C-W, Chao M-R, Sie C-H. Urinary analysis of 8-oxo-7,8-dihydroguanine and 8-oxo-7,8-dihydro-2′-deoxyguanosine by isotope-dilution LC-MS/MS with automated solid-phase extraction: study of 8-oxo-7,8-dihydroguanine stability. Free Radical Biology and Medicine. 2010;48(1):89–97.
    1. Shigenaga MK, Gimeno CJ, Ames BN. Urinary 8-hydroxy-2′-deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(24):9697–9701.
    1. Cooke MS, Olinski R, Loft S. Measurement and meaning of oxidatively modified DNA lesions in urine. Cancer Epidemiology Biomarkers and Prevention. 2008;17(1):3–14.
    1. Hu C-W, Huang Y-J, Li Y-J, Chao M-R. Correlation between concentrations of 8-oxo-7,8-dihydro-2′-deoxyguanosine in urine, plasma and saliva measured by on-line solid-phase extraction LC-MS/MS. Clinica Chimica Acta. 2010;411(17-18):1218–1222.
    1. Schiffmann D, de Boni U. Dislocation of chromatin elements in prophase induced by diethylstilbestrol: a novel mechanism by which micronuclei can arise. Mutation Research. 1991;246(1):113–122.
    1. Stopper H, Müller SO. Micronuclei as a biological endpoint for genotoxicity: a minireview. Toxicology In Vitro. 1997;11(5):661–667.
    1. Cengiz K, Block AMW, Hossfeld DK, Anthone R, Anthone S, Sandberg AA. Sister chromatid exchange and chromosome abnormalities in uremic patients. Cancer Genetics and Cytogenetics. 1988;36(1):55–67.
    1. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Experimental Cell Research. 1988;175(1):184–191.
    1. Kassie F, Parzefall W, Knasmüller S. Single cell gel electrophoresis assay: a new technique for human biomonitoring studies. Mutation Research. 2000;463(1):13–31.
    1. Stopper H, Schupp N, Klassen A, Sebekova K, Heidland A. Genomic damage in chronic renal failure: potential therapeutic interventions. Journal of Renal Nutrition. 2005;15(1):81–86.
    1. Wei Y-H. Mitochondrial DNA alterations as ageing-associated molecular events. Mutation Research. 1992;275(3–6):145–155.
    1. Liu C-S, Ko L-Y, Lim P-S, Kao S-H, Wei Y-H. Biomarkers of DNA damage in patients with end-stage renal disease: mitochondrial DNA mutation in hair follicles. Nephrology Dialysis Transplantation. 2001;16(3):561–565.
    1. Stoyanova E, Sandoval SB, Zúñiga LA, et al. Oxidative DNA damage in chronic renal failure patients. Nephrology Dialysis Transplantation. 2010;25(3):879–885.
    1. Granata S, Zaza G, Simone S, et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics. 2009;10, article 388
    1. Stopper H, Boullay F, Heidland A, Vienken J, Bahner U. Comet-assay analysis identifies genomic damage in lymphocytes of uremic patients. The American Journal of Kidney Diseases. 2001;38:296–301.
    1. Malachi T, Zevin D, Gafter U, Chagnac A, Slor H, Levi J. DNA repair and recovery of RNA synthesis in uremic patients. Kidney International. 1993;44(2):385–389.
    1. Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-κB, and glutathione S-transferase gene expression. Journal of Biological Chemistry. 1996;271(23):13422–13429.
    1. Anilkumar N, Weber R, Zhang M, Brewer A, Shah AM. Nox4 and Nox2 NADPH oxidases mediate distinct cellular redox signaling responses to agonist stimulation. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28(7):1347–1354.
    1. Vayalil PK, Iles KE, Choi J, Yi A-K, Postlethwait EM, Liu R-M. Glutathione suppresses TGF-β-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter. The American Journal of Physiology. 2007;293(5):L1281–L1292.
    1. Vayalil PK, Olman M, Murphy-Ullrich JE, Postlethwait EM, Liu R-M. Glutathione restores collagen degradation in TGF-β-treated fibroblasts by blocking plasminogen activator inhibitor-1 expression and activating plasminogen. The American Journal of Physiology. 2005;289(6):L937–L945.
    1. Wu C-C, Chen J-S, Lin S-H, et al. Aberrant activation of the TNF-α system and production of fas and scavenger receptors on monocytes in patients with end-stage renal disease. Artificial Organs. 2005;29(9):701–707.
    1. Galli F, Ghibelli L, Buoncristiani U, et al. Mononuclear leukocyte apoptosis in haemodialysis patients: the role of cell thiols and vitamin E. Nephrology Dialysis Transplantation. 2003;18(8):1592–1600.
    1. Wu C-C, Liao T-N, Lu K-C, et al. Apoptotic markers on lymphocytes and monocytes are unchanged during single hemodialysis sessions using either regenerated cellulose or polysulfone membranes. Clinical Nephrology. 2005;64(3):198–204.
    1. London GM, Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney International. 1997;51(6):1678–1695.
    1. Aviram M, Rosenblat M, Etzioni A, Levy R. Activation of NADPH oxidase is required for macrophage-mediated oxidation of low-density lipoprotein. Metabolism. 1996;45(9):1069–1079.
    1. Xia Y, Tsai A-L, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase: a Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. Journal of Biological Chemistry. 1998;273(40):25804–25808.
    1. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annual Review of Medicine. 1997;48:489–509.
    1. Miyata T, Oda O, Inagi R, et al. β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. Journal of Clinical Investigation. 1993;92(3):1243–1252.
    1. Capeillere-Blandin C, Delaveau T, Descamps-Latscha B. Structural modifications of human β2 microglobulin treated with oxygen-derived radicals. Biochemical Journal. 1991;277(1):175–182.
    1. Šebeková K, Wagner Z, Schupp N, Boor P. Genomic damage and malignancy in end-stage renal failure: do advanced glycation end products contribute? Kidney and Blood Pressure Research. 2007;30(1):56–66.
    1. Loft S, Poulsen HE. Cancer risk and oxidative DNA damage in man. Journal of Molecular Medicine. 1996;74:297–312.
    1. Stopper H, Schupp N, Bahner U, Sebekova K, Klassen A, Heidland A. Genomic damage in end-stage renal failure: potential involvement of advanced glycation end products and carbonyl stress. Seminars in Nephrology. 2004;24(5):474–478.
    1. Himmelfarb J, Hakim RM. Oxidative stress in uremia. Current Opinion in Nephrology and Hypertension. 2003;12:593–598.
    1. Devaraj S, Jialal I. The effects of alpha-tocopherol on critical cells in atherogenesis. Current Opinion in Lipidology. 1998;9(1):11–15.
    1. Diaz MN, Frei B, Vita JA, Keaney JF., Jr. Antioxidants and atherosclerotic heart disease. The New England Journal of Medicine. 1997;337(6):408–416.
    1. Brunet J, Boily M-J, Cordeau S, Des Rosiers C. Effects of N-acetylcysteine in the rat heart reperfused after low-flow ischemia: evidence for a direct scavenging of hydroxyl radicals and a nitric oxide-dependent increase in coronary flow. Free Radical Biology and Medicine. 1995;19(5):627–638.
    1. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R. N-acetyl cysteine ameliorates ischemic renal failure. The American Journal of Physiology. 1997;272(3):F292–F298.
    1. Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. Journal of the American College of Cardiology. 2001;37(1):117–123.
    1. Hsu S-P, Chiang C-K, Yang S-Y, Chien C-T. N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients. Nephron. 2010;116(3):c207–c216.
    1. Libetta C, Sepe V, Esposito P, Galli F, Dal Canton A. Oxidative stress and inflammation: implications in uremia and hemodialysis. Clinical Biochemistry. 2011;44(14-15):1189–1198.
    1. Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation. 2002;105(3):393–396.
    1. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal J-F, Michel J-B. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-κB activation induced by intracellular oxidative stress. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20(3):645–651.
    1. Imaeda A, Tanigawa T, Aoki T, Kondo Y, Nakamura N, Yoshikawa T. Antioxidative effects of fluvastatin and its metabolites against oxidative DNA damage in mammalian cultured cells. Free Radical Research. 2001;35(6):789–801.
    1. Wautier M-P, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier J-L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. The American Journal of Physiology. 2001;280(5):E685–E694.
    1. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovascular Research. 1998;37(3):586–600.
    1. Krivosíková Z, Dusinská M, Spustová V, et al. DNA damage of lymphocytes in experimental chronic renal failure: beneficial effects of losartan. Kidney International. 2001;78(supplement):S212–S215.
    1. Moberly JB, Logan J, Borum PR, et al. Elevation of whole-blood glutathione in peritoneal dialysis patients by L-2-oxothiazolidine-4-carboxylate, a cysteine prodrug (procysteine) Journal of the American Society of Nephrology. 1998;9(6):1093–1099.
    1. Stopper H, Treutlein A-T, Bahner U, et al. Reduction of the genomic damage level in haemodialysis patients by folic acid and vitamin B12 supplementation. Nephrology Dialysis Transplantation. 2008;23(10):3272–3279.
    1. Heinz J, Kropf S, Luley C, Dierkes J. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. The American Journal of Kidney Diseases. 2009;54(3):478–489.
    1. Wang X, Fenech M. A comparison of folic acid and 5-methyltetrahydrofolate for prevention of DNA damage and cell death in human lymphocytes in vitro. Mutagenesis. 2003;18(1):81–86.
    1. Fenech M, Baghurst P, Luderer W, et al. Low intake of calcium, folate, nicotinic acid, vitamin E, retinol, β-carotene and high intake of pantothenic acid, biotin and riboflavin are significantly associated with increased genome instability: results from a dietary intake and micronucleus index survey in South Australia. Carcinogenesis. 2005;26(5):991–999.
    1. MacGregor JT, Wehr CM, Hiatt RA, et al. ‘Spontaneous’ genetic damage in man: evaluation of interindividual variability, relationship among markers of damage, and influence of nutritional status. Mutation Research. 1997;377(1):125–135.
    1. Titenko-Holland N, Jacob RA, Shang N, Balaraman A, Smith MT. Micronuclei in lymphocytes and exfoliated buccal cells of postmenopausal women with dietary changes in folate. Mutation Research. 1998;417(2-3):101–114.
    1. Ruiz S, Pergola PE, Zager RA, Vaziri ND. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney International. 2013;83:1029–1041.
    1. Dinkova-Kostova AT, Liby KT, Stephenson KK, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(12):4584–4589.
    1. Yates MS, Tauchi M, Katsuoka F, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Molecular Cancer Therapeutics. 2007;6(1):154–162.
    1. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. Journal of Natural Products. 2011;74(3):537–545.
    1. Levonen A-L, Landar A, Ramachandran A, et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochemical Journal. 2004;378(2):373–382.
    1. Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D. Triterpenoid CDDO-Me blocks the NF-κB pathway by direct inhibition of IKKβ on Cys-179. Journal of Biological Chemistry. 2006;281(47):35764–35769.
    1. Floridi A, Antolini F, Galli F, Fagugli RM, Floridi E, Buoncristiani U. Daily haemodialysis improves indices of protein glycation. Nephrology Dialysis Transplantation. 2002;17(5):871–878.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever